Evan F Garner1, Ilan I Maizlin1, Matthew B Dellinger2, Kenneth W Gow2, Melanie Goldfarb3, Adam B Goldin2, John J Doski4, Monica Langer5, Jed G Nuchtern6, Sanjeev A Vasudevan6, Mehul V Raval7, Elizabeth A Beierle8. 1. Department of Surgery, University of Alabama at Birmingham, Birmingham, AL. 2. Division of Pediatric General and Thoracic Surgery, Seattle Children's Hospital, Seattle, WA. 3. Department of Surgery, John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, CA. 4. Department of Surgery, Methodist Children's Hospital of South Texas, University of Texas Health Science Center-San Antonio, San Antonio, TX. 5. Department of Surgery, Maine Children's Cancer Program, Tufts University, Portland, ME. 6. Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Texas Children's Hospital, Houston, TX. 7. Division of Pediatric Surgery, Department of Surgery, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA. 8. Department of Surgery, University of Alabama at Birmingham, Birmingham, AL. Electronic address: elizabeth.beierle@childrensal.org.
Abstract
BACKGROUND: Well-differentiated thyroid cancer is the most common endocrine malignancy in children. Adult literature has demonstrated socioeconomic disparities in patients undergoing thyroidectomy, but the effects of socioeconomic status on the management of pediatric well-differentiated thyroid cancer remains poorly understood. METHODS: Patients ≤21 years of age with well-differentiated thyroid cancer remains were reviewed from the National Cancer Data Base. Three socioeconomic surrogate variables were identified: insurance type, median income, and educational quartile. Tumor characteristics, diagnostic intervals, and clinical outcomes were compared within each socioeconomic surrogate variable. RESULTS: A total of 9,585 children with well-differentiated thyroid cancer remains were reviewed. In multivariate analysis, lower income, lower educational quartile, and insurance status were associated with higher stage at diagnosis. Furthermore, lower income quartile was associated with a longer time from diagnosis to treatment (P < .002). Similarly, uninsured children had a longer time from diagnosis to treatment (28 days) compared with those with government (19 days) or private (18 days) insurance (P < .001). Despite being diagnosed at a higher stage and having a longer time interval between diagnosis and treatment, there was no significant difference in either overall survival or rates of unplanned readmissions based on any of the socioeconomic surrogate variables. CONCLUSION: Children from lower income families and those lacking insurance experienced a longer period from diagnosis to treatment of their well-differentiated thyroid cancer remains. These patients also presented with higher stage disease. These data suggest a delay in care for children from low-income families. Although these findings did not translate into worse outcomes for well-differentiated thyroid cancer remains, future efforts should focus on reducing these differences.
BACKGROUND: Well-differentiated thyroid cancer is the most common endocrine malignancy in children. Adult literature has demonstrated socioeconomic disparities in patients undergoing thyroidectomy, but the effects of socioeconomic status on the management of pediatric well-differentiated thyroid cancer remains poorly understood. METHODS:Patients ≤21 years of age with well-differentiated thyroid cancer remains were reviewed from the National Cancer Data Base. Three socioeconomic surrogate variables were identified: insurance type, median income, and educational quartile. Tumor characteristics, diagnostic intervals, and clinical outcomes were compared within each socioeconomic surrogate variable. RESULTS: A total of 9,585 children with well-differentiated thyroid cancer remains were reviewed. In multivariate analysis, lower income, lower educational quartile, and insurance status were associated with higher stage at diagnosis. Furthermore, lower income quartile was associated with a longer time from diagnosis to treatment (P < .002). Similarly, uninsured children had a longer time from diagnosis to treatment (28 days) compared with those with government (19 days) or private (18 days) insurance (P < .001). Despite being diagnosed at a higher stage and having a longer time interval between diagnosis and treatment, there was no significant difference in either overall survival or rates of unplanned readmissions based on any of the socioeconomic surrogate variables. CONCLUSION:Children from lower income families and those lacking insurance experienced a longer period from diagnosis to treatment of their well-differentiated thyroid cancer remains. These patients also presented with higher stage disease. These data suggest a delay in care for children from low-income families. Although these findings did not translate into worse outcomes for well-differentiated thyroid cancer remains, future efforts should focus on reducing these differences.
Authors: Megan R Haymart; Mousumi Banerjee; Andrew K Stewart; Ronald J Koenig; John D Birkmeyer; Jennifer J Griggs Journal: JAMA Date: 2011-08-17 Impact factor: 56.272
Authors: John E Scarborough; Ricardo Pietrobon; Bryan M Clary; Carlos E Marroquin; Kyla M Bennett; Paul C Kuo; Theodore N Pappas Journal: J Am Coll Surg Date: 2008-08-30 Impact factor: 6.113
Authors: Anna E Bargren; Goswin Y Meyer-Rochow; Leigh W Delbridge; Stan B Sidhu; Herbert Chen Journal: J Surg Res Date: 2009-05-12 Impact factor: 2.192
Authors: Katherine Mallin; Bryan E Palis; Nancy Watroba; Andrew K Stewart; Daniel Walczak; Joseph Singer; John Barron; Wendy Blumenthal; Georgette Haydu; Stephen B Edge Journal: J Am Coll Surg Date: 2013-01-26 Impact factor: 6.113
Authors: Warren C Swegal; Michael Singer; Edward Peterson; Heather Spencer Feigelson; Scott A Kono; Susan Snyder; Thuy-Anh N Melvin; Gabriel Calzada; Nirupa R Ghai; Daniel M Saman; Steven S Chang Journal: Otolaryngol Head Neck Surg Date: 2015-12-15 Impact factor: 3.497
Authors: Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J A Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth Journal: Cancer Epidemiol Date: 2021-09-28 Impact factor: 2.984
Authors: Amy M Berkman; Clark R Andersen; Branko Cuglievan; David C McCall; Philip J Lupo; Susan K Parsons; Courtney D DiNardo; Nicholas J Short; Nitin Jain; Tapan M Kadia; J A Livingston; Michael E Roth Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-06-01 Impact factor: 4.090
Authors: Hanna Mogensen; Karin Modig; Giorgio Tettamanti; Friederike Erdmann; Mats Heyman; Maria Feychting Journal: Front Oncol Date: 2018-10-31 Impact factor: 6.244
Authors: Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J Andrew Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-07-08 Impact factor: 4.254